Inhibitory effects of anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice

Rheumatology

Volumn 42, Issue 11, 2003, Pages 1365-1371

  Tanaka, Keiichi ^c   Yamamoto, T ^c   Aikawa, Y ^c   Kizawa, K ^c   Muramoto, K ^a   Matsuno, H ^b   Muraguchi, A ^b  

^a EISAI CO LTD   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

^c TOYAMA CHEMICAL CO LTD   (Japan)

Author keywords

Immunoglobulin production; Rheumatoid arthritis; SCID mouse; Synovial tissue; T 614

Indexed keywords

ANTIRHEUMATIC AGENT; CD3 ANTIGEN; IGURATIMOD; IMMUNOGLOBULIN G; INTERLEUKIN 4; LIPOPOLYSACCHARIDE; LYMPHOCYTE ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; BLOOD DONOR; CELL ISOLATION; CELL STIMULATION; COCULTURE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG MECHANISM; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN PRODUCTION; LYMPHOCYTE CULTURE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCID MOUSE; SYNOVIUM; T LYMPHOCYTE;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; BENZOPYRANS; CELL DIVISION; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED BALB C; MICE, SCID; SULFONAMIDES; SYNOVIAL MEMBRANE;

EID: 0242609352     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keg381     Document Type: Article

References (22)

1. Tanaka K, Aikawa Y, Kawasaki H, Asaoka K, Inaba T, Yoshida C. Pharmacological studies on 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one (T-614), a novel antiinflammatory agent. Inhibitory effect on the production of interleukin-1 and interleukin-6. J Pharmacobio-Dyn 1992;15:649-55.
2. Kawakami A, Tsuboi M, Urayama S et al. Inhibitory effect of a new anti-rheumatic drug T-614 in costimulatory molecule expression, cytokine production, and antigen presentation by synovial cells. J Lab Clin Med 1999;133:566-74.
3. Tracey D. Interleukin-1 as a therapeutic target. Annu Rep Med Chem 1994;29:205-14.
4. Tanaka K, Shimotori T, Taniguchi Y, Eguchi M, Abe C. Pharmacological studies of T-614, a novel antiinflammaory agent. Effect on type II collagen-induced arthritis in DBA/1J mice and spontaneous arthritis in MRL/1 mice. Int J Immunother 1993;9:69-78.
5. Inaba T, Tanaka K, Takeno R, Nagaki H, Yoshida C, Takano S. Synthesis and antiinflammatory activity of 7-methanesulfonylamino-6-phenoxychromones; Antiarthritic effect of the formylamino compound (T-614) in chronic inflammatory disease models. Chem Pharm Bull 2000; 48:131-9.
6. Aikawa Y, Tanuma N, Shin T, Makino S, Tanaka K, Matsumoto Y. A new anti-rheumatic drug, T-614, effectively suppresses the development of autoimmune encephalomyelitis. J Neuroimmunol 1998;89:35-42.
7. Hara M, Kashiwazaki S, Abe T et al. Therapeutic effect of T-614, a new anti-arthritic agent, on rheumatoid arthritis. Arthritis Rheum 1996;39(Suppl.):S282.
8. Matsuno H, Sawai T, Nezuka T et al. Treatment of rheumatoid synovitis with anti-reshaping human interleukin-6 receptor monoclonal antibody: use of rheumatoid arthritis tissue implants in the SCID mouse model. Arthritis Rheum 1998;41:2014-21.
9. Sakai K, Matsuno H, Morita I et al. Potential withdrawal of rheumatoid synovium by the induction of apoptosis using a novel in vivo model of rheumatoid arthritis. Arthritis Rheum 1998;41:1251-7.
10. Coffman RL, Ohara J, Bond MW, Carty J, Zlotnik A, Paul WE. B cell stimulatory factor-1 enhances the IgE response of lipopolysaccharide-activated B cells. J Immunol 1986; 136:4538-41.
11. Mond JJ, Brunswick M. In vitro assays for mouse B and T cells function. Isolation of B cells by percoll gradient centrifugation. In: Coligan JE et al., eds. Current protocols in immunology. New York: John Wiley & Sons, 1991:3.8.11-16.
12. Scudiero DA. Evaluation of a soluble tetrazorium/formazan assay for cell growth and drug sensitivity in culture using human and tumor cell lines. Cancer Res 1988;48:4827-33.
13. Coffman RL, Carty J. A T cell activity that enhances polyclonal IgE production and its inhibition by interferon-γ. J Immunol 1986;136:949-54.
14. Nakazawa F, Matsuno H, Yudoh K et al. Methotrexate inhibits rheumatoid synovitis by inducing apoptosis. J Rheumatol 2001;28:1800-8.
15. Matsuno H, Yudoh K, Katayama R et al. The role of TNF-α in the pathogenesis of inflammation and joint destruction in rheumatoid arthritis (RA): a study using a human RA/SCID mouse chimera. Rheumatology 2002; 41:329-37.
16. Matsuno H, Yudoh K, Uzuki M et al. Treatment with the angiogenesis inhibitor endostatin: a novel therapy in rheumatoid arthritis. J Rheumatol 2002;29:890-5.
17. Stavnezer J. Antibody class switching. Adv Immunol 1996;61:79-146.
18. Mosmann TR, Coffman RL. TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145-73.
19. Matsumoto I, Staub A, Benoist C, Mathis D. Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science 1999;286:1732-5.
20. Benoist C, Mathis D. A revival of the B cell paradigm for rheumatoid arthritis pathogenesis? Arthritis Res 2000; 2:90-4.
21. Schaller M, Burton DR, Ditzel HJ. Autoantibodies to GPI in rheumatoid arthritis: linkage between an animal model and human disease. Nat Immunol 2001;2: 746-53.
22. Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology 2001;40:205-11.